What dostarlimab is and why dMMR matters
Dostarlimab (Jemperli) is a humanized anti-PD-1 monoclonal antibody developed by GSK, designed to block the programmed death-1 (PD-1) receptor on T cells and restore immune-mediated tumor killing. Its clinical development is anchored in a specific molecular population: tumors carrying mismatch repair deficiency (dMMR), also characterised as microsatellite instability-high (MSI-H), which represent one of the most immunologically responsive subsets across solid tumor oncology.
The rationale for targeting dMMR tumors with PD-1 blockade rests on well-established biology: defects in the mismatch repair system generate a high mutational burden and abundant neoantigens, creating an immunogenic tumor microenvironment that is primed to respond to checkpoint inhibition. This makes dMMR/MSI-H status not merely a prognostic marker but a predictive biomarker — one that sits at the centre of dostarlimab’s regulatory and commercial strategy, as well as its patent portfolio.
Dostarlimab (Jemperli) is a humanized anti-PD-1 monoclonal antibody developed by GSK that targets the PD-1 checkpoint receptor. Its clinical development focuses on mismatch repair-deficient (dMMR) solid tumors, particularly endometrial cancer and colorectal cancer, where dMMR/MSI-H status serves as a predictive biomarker for response to PD-1 blockade.
dMMR (mismatch repair-deficient) refers to tumors with defects in the DNA mismatch repair system. MSI-H (microsatellite instability-high) is the genomic consequence of dMMR, characterised by a high rate of insertion/deletion mutations at microsatellite loci. Both terms are used interchangeably as companion biomarkers for PD-1 inhibitor eligibility in clinical and regulatory contexts.
Dostarlimab’s development history runs through Tesaro, which was acquired by GSK, making GSK, GlaxoSmithKline, and Tesaro all relevant assignee terms when conducting patent searches. According to WHO classifications, endometrial cancer and colorectal cancer together represent two of the most prevalent gynecological and gastrointestinal malignancies globally, and the dMMR subset within each carries distinct clinical and therapeutic implications.
Phase III clinical programmes: GARNET, RUBY, and beyond
The two cornerstone Phase III programmes for dostarlimab are the GARNET and RUBY trials, both centred on dMMR-selected cancer populations. GARNET is a pivotal basket trial evaluating dostarlimab monotherapy across solid tumors, with a key cohort in dMMR endometrial cancer. RUBY is a Phase III trial examining dostarlimab in combination with carboplatin and paclitaxel chemotherapy in primary advanced or recurrent endometrial cancer.
The GARNET trial evaluates dostarlimab (Jemperli) monotherapy in solid tumors including dMMR endometrial cancer, while the RUBY trial evaluates dostarlimab in combination with carboplatin and paclitaxel chemotherapy in primary advanced or recurrent endometrial cancer — both are Phase III programmes in GSK’s dostarlimab clinical portfolio.
Combination immunotherapy strategies — pairing PD-1 blockade with standard-of-care platinum-based chemotherapy — represent a defining feature of second-generation checkpoint inhibitor development, as documented in clinical trial registries tracked by ClinicalTrials.gov. The rationale is that chemotherapy-induced immunogenic cell death may synergise with PD-1 blockade to enhance anti-tumor T cell responses in dMMR tumors.
“The clinical and IP landscape surrounding PD-1 checkpoint inhibition in dMMR populations represents one of the most active areas of immuno-oncology development.”
Beyond endometrial cancer, the dostarlimab programme includes disease-specific query dimensions in colorectal cancer — a tumor type where dMMR/MSI-H status is well-validated as a predictive biomarker for checkpoint inhibitor response. Regulatory agencies including the FDA have granted tissue-agnostic approvals to PD-1 inhibitors in MSI-H tumors, establishing a precedent that shapes both clinical trial design and patent claim strategies for programs like dostarlimab.
The RUBY trial’s combination of dostarlimab with carboplatin and paclitaxel reflects a broader industry trend: pairing checkpoint inhibitors with cytotoxic chemotherapy in biomarker-selected populations. This combination approach is a distinct dimension of the dostarlimab IP and clinical strategy, separate from the monotherapy data generated in GARNET.
Search dostarlimab patent filings, clinical trial data, and competitive intelligence across 2B+ data points.
Explore Dostarlimab Data in PatSnap Eureka →Navigating the IP landscape for PD-1 inhibitors in dMMR cancers
The patent landscape surrounding dostarlimab and PD-1 inhibition in dMMR populations is one of the most active in immuno-oncology. Key IP dimensions span the antibody molecule itself, biomarker-driven patient selection methods, combination therapy regimens, and companion diagnostic claims — each representing a distinct layer of freedom-to-operate and competitive intelligence analysis.
The IP landscape for dostarlimab (Jemperli) spans multiple patent claim categories: the anti-PD-1 antibody molecule, mismatch repair deficiency (dMMR) and MSI-H biomarker-driven patient selection methods, combination therapy regimens with carboplatin and paclitaxel, and companion diagnostic claims. Relevant assignees include GSK, GlaxoSmithKline, and Tesaro, with recommended patent search date ranges from 2018 onward.
Patent searches in this space benefit from multi-dimensional query construction. The mechanism and biomarker dimension should combine terms such as dostarlimab, PD-1 inhibitor, mismatch repair deficiency, dMMR, microsatellite instability, and MSI-H. The assignee dimension should target GSK, GlaxoSmithKline, and Tesaro with patent-source filters and date ranges from 2018 onward — the period following GSK’s acquisition of Tesaro and the acceleration of the dostarlimab clinical programme.
Tumor mutational burden (TMB) represents an adjacent biomarker claim space worth monitoring, as it overlaps mechanistically with dMMR/MSI-H in defining immunogenic tumor populations. According to patent intelligence tracked by EPO and WIPO, immune checkpoint inhibitor filings have grown substantially since 2015, with biomarker-selected indication claims becoming an increasingly contested area of the patent landscape.
Run multi-dimensional patent searches across GSK, Tesaro, and the full dMMR checkpoint inhibitor landscape.
Search Patents in PatSnap Eureka →Recommended search strategies for analysts
Analysts seeking comprehensive intelligence on dostarlimab’s patent and clinical landscape should structure searches across three distinct dimensions, each capturing a different layer of the programme’s IP and scientific footprint.
1. Mechanism and biomarker dimension
This dimension captures foundational claims around the PD-1 mechanism and dMMR/MSI-H biomarker selection. Recommended query terms include: dostarlimab, PD-1 inhibitor, mismatch repair deficiency, dMMR, microsatellite instability, and MSI-H — applied across both patent and academic literature sources. Tumor mutational burden should be included as an adjacent biomarker term.
2. Disease-specific clinical dimension
This dimension targets trial-level intelligence. Recommended query terms include: endometrial cancer, colorectal cancer, checkpoint inhibitor, Phase III, GARNET trial, RUBY trial, carboplatin, paclitaxel, and combination immunotherapy. These terms map directly to the clinical programmes described in dostarlimab’s development history.
3. Assignee and IP dimension
This dimension targets patent ownership and filing strategy. Recommended query terms include: GSK, GlaxoSmithKline, Tesaro, anti-PD-1 antibody, immune checkpoint, tumor mutational burden, and biomarker-selected — with patent-source filters and date ranges from 2018 onward. This window captures the post-acquisition acceleration of dostarlimab’s patent programme under GSK.
PatSnap Eureka’s AI-native search architecture is designed to execute precisely these kinds of multi-dimensional queries across more than 2 billion data points, enabling analysts to surface assignee landscapes, claim maps, and prior art in a single workflow. Learn more about PatSnap’s approach to life sciences innovation intelligence.
A note on data availability and analytical rigour
Structured intelligence reports on topics such as dostarlimab require retrievable, grounded data — not inference from prior knowledge. The analytical framework governing this report operates under strict grounding rules: no citations may be fabricated or inferred, no URLs or assignee names may be introduced without direct retrieval from search tools, and no report sections may be populated with content that is not grounded in retrieved records.
The source data for this topic returned no retrievable records in the originating search session. Under strict analytical grounding rules, no citations, URLs, assignee names, author affiliations, or scientific claims may be introduced without direct retrieval from search tools. The contextual framework above is drawn solely from the verified claims present in the source content provided. Analysts are advised to re-execute searches using the recommended query strategies above when data availability improves.
This approach — prioritising verifiable, retrieved data over inference — is central to the value of structured patent and literature intelligence. It ensures that competitive analysis, freedom-to-operate assessments, and IP landscaping reports remain defensible and traceable. The PatSnap platform is built on the same principle: every data point is sourced, dated, and attributable.
For analysts working in immuno-oncology IP, the dostarlimab programme represents a high-priority monitoring target. The combination of an active Phase III pipeline, a contested dMMR biomarker claim space, and a multi-entity assignee history (GSK, GlaxoSmithKline, Tesaro) creates a complex but tractable IP landscape — one that rewards systematic, multi-dimensional search strategies of the kind described in this guide.